RESEARCHPAPER
HumanVaccines&Immunotherapeutics11:2,358--376;February2015;©2015Taylor&FrancisGroup,LLC
Immunogenicity and safety of cell-derived
(cid:1) fl
MF59 -adjuvanted A/H1N1 in uenza vaccine
for children
MarkusKnuf1,2,*,GeertLeroux-Roels3,HansRu€mke4,LuisRivera5,PaolaPedotti6,AshwaniKumarArora7,MariaLattanzi7,
DorotheeKieninger2,andGiovanniDellaCioppa7
1ClinicforChildrenandYouth;Dr.HorstSchmidtClinics;Wiesbaden,Germany;2CenterforChildrenandYouthMedicine;UniversityofMedicine;Mainz,Rheinland-Pfalz,Germany;
3CenterforVaccinology;GhentUniversityandUniversityHospital;Ghent,Belgium;4VaxinosticsBV;UniversityVaccineCenterRotterdamNijmegen;Rotterdam,Netherlands;
5HospitalMaternidadNuestraSen~oradelaAltagracia;Gazcue,SantoDomingo,DominicanRepublic;6NovartisPharmaBV;Amsterdam,TheNetherlands;7NovartisVaccinesand
DiagnosticsSrl;Siena,Italy
Keywords:adjuvant,cell-culture,H1N1,MF59,pandemic,pediatric
Abbreviations:AE,adverseevent;CHMP,EuropeanCommitteeforMedicinalProductsforHumanUse;CI,confidenceinterval;
GMR,geometricmeanratio;GMT,geometricmeantiter;HI,hemagglutinationinhibition;MN,microneutralization;PPS,
per-protocolset;SAE,seriousadverseevent;WHO,WorldHealthOrganization
Mass immunization of children has the potential to decrease infection rates and prevent the transmission of
influenza. We evaluated the immunogenicity, safety, and tolerability of different formulations of cell-derived MF59-
adjuvantedandnonadjuvantedA/H1N1influenzavaccineinchildrenandadolescents.Thiswasarandomized,single-
blind,multicenterstudywithatotalof666healthysubjectsaged6months–17yinoneof3vaccinationgroups,each
receiving formulations containing different amounts of influenza A/H1N1 antigen with or without MF59. A booster
trivalentseasonalMF59vaccinewasadministeredoneyearafterprimaryvaccinations.Antibodytiterswereassessedby
hemagglutinationinhibition(HI)andmicroneutralizationassaysobtainedondays1,22,43,366,and387(3weekspost
booster). Safety was monitored throughout the study. One vaccination with 3.75 mg of A/H1N1 antigen formulated
with50%MF59(3.75_halfMF59)or7.5 mgofA/H1N1antigenformulatedwith100%MF59(7.5_fullMF59)inducedanHI
titer (cid:1)1:40 in >70% of children in the 1–<3, 3–8, and 9–17 y cohorts; however, 2 vaccinations with nonadjuvanted
15mgA/H1N1antigenwereneededtoachievethisresponseinthe1–<3and3–8ycohorts.Amongchildrenaged6–
11months,1doseof7.5_fullMF59resultedinanHItiter(cid:1)1:40in>70%while2dosesof3.75_halfMF59wererequired
to achieve this result. All vaccines were well tolerated. Our findings support the immunogenicity and safety of the
3.75_halfMF59 (2 doses for children <12 months) and 7.5_fullMF59 vaccine formulations for use in children and
adolescents aged 6 months to 17 y The use of the 3.75_halfMF59 could have the benefit of antigen and adjuvant
sparing,increasingtheavailablevaccinedosesallowingvaccinationofmorepeople.
Introduction Health authorities and vaccine manufacturers have focused on
the development of vaccines based on the A/California/7/2009
Young people from birth to 18 y of age were at significantly viralstrain,withvariousadjuvantedandnonadjuvantedformula-
higher risk from the 2009 A/H1N1 influenza pandemic than tionsproducedusingbothtraditionalandnovelmethods.10One
older adults,1-3 with the most severe infections initially reported important advance in the manufacture of influenza vaccines is
inchildren.4Estimatessuggestthatthecumulativerateofdevel- the use of cell-culture to replace traditional egg-based produc-
opingclinicalillnesswasincreasedby30-to80-foldamongpeo- tion. This technology is not dependent on the availability of
ple aged (cid:3)24 years comparedwith individuals aged(cid:1)65 years.1 eggs, and facilitates enhanced manufacturing control and poten-
Inadditiontotheirheightenedsusceptibilitytoseasonalandpan- tially reduction in production lead times, all of which could be
demicinfluenzaviruses,childrenarealsoimportantcontributors pivotalintheeventofanotherinfluenzapandemic.Anumberof
tovirustransmission.5,6 controlledclinicaltrialsconfirmthatoil-in-wateradjuvants,such
Mass immunization of children is considered essential to asMF59,meetthequalitiesrequiredofasafevaccinefordiverse
achieve disease control that will decrease infection rates and the populations.11-19Inaddition,MF59hasbeenshowntoheighten
risk of viral transmission within families and communities.6-9 antibody response to the A/H1N1 pandemic virus18,20–24 and
*Correspondenceto:MarkusKnuf;Email:markus.knuf@hsk-wiesbaden.de
Submitted:07/30/2014;Revised:09/15/2014;Accepted:09/22/2014
http://dx.doi.org/10.4161/21645515.2014.987014
358 HumanVaccines&Immunotherapeutics Volume11Issue2
has been endorsed by the World Health Organization (WHO) increased 47-fold in the 3.75_halfMF59 group and 80-fold in
for this indication.25 This study evaluated the immunogenicity, the 7.5_fullMF59 group (Table 2). There were 6- to 14-fold
safety, and tolerability of different formulations of cell-derived increases in GMT across the 3 vaccine groups at day 22 for
MF59-adjuvanted and nonadjuvanted A/H1N1 vaccine in cohort2 (3–8 years),with 28-to115-foldincreases across the3
healthychildrenandadolescents. vaccinegroupsbyday43(Table2).HigherGMTswereevident
for both adjuvanted groups compared with the nonadjuvanted
group (Table 2). Three weeks following the first vaccination for
Results cohort3(1–<3 years),therewasa6-to7-foldincreaseinGMT
frombaselineintheadjuvantedvaccinegroupscomparedwitha
A total of 666 subjects were enrolled (cohort 1; n D 159; 2-fold increase in the nonadjuvanted group (Table 2). By day
cohort2;nD184;cohort3;nD172;cohort4;nD151).Data 43, there was an 89- to 108-fold increase in GMT in the adju-
fromonesite(nD86)wereexcludedfromtheanalysisasaresult vanted groups and an 11-fold increase in the nonadjuvanted
of noncompliance with protocol requirements for a different group (Table 2). At day 22, there was an approximate 5- to 10-
clinical study. Subject disposition and demographics are shown fold increasein GMT inthe3.75_halfMF59 and7.5_fullMF59
inFigure1andTable1,respectively. groups, respectively, in cohort 4 (6–11 months), with a 92- to
129-foldincreasebyday43(Table2).
All three European Committee for Medicinal Products for
Immunogenicity
Human Use (CHMP) criteria were met for both the nonadju-
Figure2showsthecumulativepercentageofsubjectsbyhem-
vanted and adjuvanted groups following the second vaccination
agglutinationinhibition(HI)titerfollowingtheinitialinjections
(day43)inallcohorts(Tables3and4).Followingthefirstvacci-
(upto43 days)inthe4cohorts.Incohort1(9–17 years),there
nation (day 22) for the adjuvanted formulations, the 3 CHMP
were 13- and 24-fold increases in geometric mean titer (GMT)
criteriaweremetincohorts1,2,and3andinthe7.5_fullMF59
inthe3.75_halfMF59and7.5_fullMF59vaccinegroups,respec-
group in cohort 4. The 3.75_halfMF59 group in cohort 4 did
tively, 3 weeks following the first vaccination (Table 2). By day
notmeetthecriterionofHI(cid:1)1:40atday22butmettheother2
43 (3 weeks following the second vaccination), GMT had
Figure1.Subjectdispositionineachagecohortandvaccinegroup.*Nvaluesincludeblooddrawsoutsidethespecifiedtimewindow;yFourthvaccina-
tiontobedoneonlyonthesubsetofna€ıvesubjects<9yearsofage.HI–hemagglutinationinhibition.
www.tandfonline.com HumanVaccines&Immunotherapeutics 359
)etistnailpmoc-nongnidulcxe,noitalupopdellorne(4dna3,2,1strohocnistcejbusfoscitsiretcarahcenilesabrehtodnascihpargomeD.1elbaT
)sraey8–3(2trohoC
)sraey71–9(1trohoC
latoT
95FMonCgm51
95FMllufCgm5.7
95FMflahCgm57.3
latoT
95FMllufCgm5.7
95FMflahCgm57.3
)481Dn(
)93Dn(
)37Dn(
)27Dn(
)951Dn(
)97Dn(
)08Dn(
7.1§3.5
5.1§2.5
7.1§3.5
9.1§5.5
7.2§2.31
7.2§2.31
7.2§2.31
DS§
naem,)sraey(egA
5.22§1.07
1.02§4.86
6.12§6.96
7.42§6.17
0.23§2.761
4.13§5.761
7.23§9.661
DS§
naem,)shtnom(egA
)%(n,xeS
)54(38
)63(41
)85(24
)83(72
)15(18
)35(24
)94(93
elaM
)55(101
)46(52
)24(13
)36(54
)94(87
)74(73
)15(14
elameF
)%(n,nigirocinhtE
)1(2
)3(1
)1(1
0
)1(2
0
)3(2
naisA
)3(5
0
)3(2
)4(3
0
0
0
kcalB
)19(861
)78(43
)69(07
)98(46
)89(651
)001(97
)69(77
naisacuaC
)1(2
0
0
)3(2
0
0
0
cinapsiH
)4(7
)01(4
0
)4(3
)1<(1
0
)1(1
rehtO
3.21§2.511
4.11§0.311
5.11§8.411
5.31§8.611
7.51§3.951
6.51§8.951
0.61§8.851
DS§
naem,)mc(thgieH
9.5§7.12
9.5§1.12
3.5§6.12
5.6§1.22
9.51§9.15
2.61§5.25
7.51§4.15
DS§
naem,)gk(thgieW
4.2§1.61
1.2§2.61
7.1§1.61
0.3§0.61
0.4§0.02
6.4§2.02
3.3§9.91
§
naem,)2m/gk(xednissamydoB
DS
)32(24
)12(8
)22(61
)52(81
)32(63
)82(22
)81(41
,noitaniccavazneuflnisuoiverP
)%(n
)shtnom11–6(4trohoC
)sraey3<–1(3trohoC
)151Dn(latoT
95FMllufCgm5.7
95FMflahCgm57.3
latoT
95FMonCgm51
95FMllufCgm5.7
95FMflahCgm57.3
)67Dn(
)57Dn(
)271Dn(
)53Dn(
)17Dn(
)66Dn(
6.1§9.8
7.1§
8.8
5.1§9.8
3.7§6.22
8.7§1.32
1.7§1.32
3.7§8.12
DS§
naem,)shtnom(egA
)%(n,xeS
)64(96
)54(43
)74(53
)75(89
)75(02
)56(64
)84(23
elaM
)45(28
)55(24
)35(04
)34(47
)34(51
)53(52
)25(43
elameF
)%(n,nigirocinhtE
0
0
0
)3(6
)6(2
)3(2
)3(2
naisA
)2(3
)4(3
0
)2(4
)3(1
)1(1
)3(2
kcalB
)51(22
)31(01
)61(21
)75(89
)45(91
)95(24
)65(73
naisacuaC
)38(521
)28(26
)48(36
)63(26
)73(31
)53(52
)63(42
cinapsiH
)1<(1
)1(1
0
)1(2
0
)1(1
)2(1
rehtO
4.4§4.17
0.4§4.17
8.4§4.17
4.7§9.48
2.7§0.58
8.7§7.58
0.7§9.38
DS§
naem,)mc(thgieH
4.1§1.9
4.1§1.9
3.1§1.9
4.2§6.21
1.2§0.21
6.2§0.31
4.2§5.21
DS§
naem,)gk(thgieW
4.2§9.71
5.2§9.71
4.2§0.81
7.2§5.71
2.2§7.61
1.3§8.71
6.2§7.71
§
naem,)2m/gk(xednissamydoB
DS
0
0
0
)8(31
)9(3
)7(5
)8(5
n,noitaniccavazneuflnisuoiverP
)%(
noitaiveddradnats,DS
360 HumanVaccines&Immunotherapeutics Volume11Issue2
Figure2.Reversecumulativedistributionofhemagglutinationinhibition(HI)titersincohort1(A),cohort2(B),cohort3(C)andcohort4(D)ondays1,
22and43.
CHMPcriteria.Atday22,the15 mgnonadjuvantedgroupmet (cid:1)1:330 with no difference between subjects primed with adju-
theCHMPgeometricmeanratio(GMR)andseroconversioncri- vantedornon-adjuvantedformulations.
teria but not the HI (cid:1)1:40 criterion in cohort 2, and did not Analysis of results from the microneutralization (MN) titer
meetanyCHMPcriteriaincohort3. assay revealed findings consistent with those for the HI assay,
One year after the primary vaccinations, hemagglutinating with the percentage of subjects with MN titer (cid:1)1:40 substan-
antibodieswerestillpresentinallvaccinegroupsinsubjectsofall tially increased after the first and second vaccinations. The MN
4 cohorts, with a trend to higher HI titers in subjects primed resultsforcohorts2and3wereconsistentlylowerforthenonad-
with 7.5_fullMF59 (Table 3). In addition, greater persistence juvanted groups. However, almost all subjects in the 3 vaccine
wasachievedincohorts2and3inresponsetobothdosesofthe groupsincohorts2and3demonstrateda4-foldincreaseinMN
adjuvantedformulationvs.thenonadjuvantedvaccine(Table3). titersfollowingthesecondvaccination.A4-foldincreaseinMN
Followingtheboostervaccination,allvaccinegroupsandcohorts titers was evident 3 weeks after the first vaccination for approxi-
achievedanHItiter(cid:1)1:40. mately 50% of subjects in both vaccine groups in cohort 4,
For the post-hoc analysis using an HI titer cutoff of (cid:1)1:330, increasing to 100% at 3 weeks following the second vaccination
at day 43, 49–94% of subjects receiving the adjuvantedvaccines (Table6).
achievedthistiter(Table5),whileonly10%and24%ofsubjects
achieved thistiter following vaccination with the nonadjuvanted Safety
vaccinesin cohorts2and3,respectively.There wasnoapparent For all formulations of study vaccine, the majority of soli-
difference betweenthe 2 adjuvanted formulations in the percen- cited local and systemic reactions were considered to be mild
tages of subjects achieving HI titers (cid:1)1:330. Following the or moderate and most subjects recovered within 7 d of onset
booster vaccination, 90–100% of subjects achieved an HI titer without sequelae (Tables 7 and 8). The rate of local and sys-
temic reactions was lower after the second vaccination for all
www.tandfonline.com HumanVaccines&Immunotherapeutics 361
*teslocotorp-rep,yassanoitibihninoitanitulggameh–)RMG(soitarnaemcirtemoegdna)TMG(sretitnaemcirtemoeG.2elbaT
4trohoC
3trohoC
2trohoC
1trohoC
)shtnom11–6(
)sraey3<–1(
)sraey8–3(
)sraey71–9(
MllufCgm5.7
gm57.3
gm51
gm5.7
gm57.3
gm51
gm5.7
gm57.3
gm5.7
gm57.3
95F
MflahC
MonC
MllufC
MflahC
MonC
MllufC
MflahC
MllufC
MflahC
)45Dn(
95F
95F
95F
95F
95F
95F
95F
95F
95F
)85Dn(
)52Dn(
)35Dn(
)15Dn(
)13Dn(
)06Dn(
)85Dn(
)17Dn(
)27Dn(
)12–53.3(33.8
)12–73.3(53.8
)32–97.5(21
)41–10.5(25.8
)31–80.4(33.7
)80.6–57.4(83.5
)49.5–9.4(93.5
)62.6–1.5(56.5
)10.7–98.4(68.5
)1.8–85.5(27.6
1yadTMG
)282–42(28
)841–31(34
)45–62.9(22
)321–23(36
)19–12(34
)65–12(53
)701–05(37
)09–14(16
)302–79(041
)131–16(09
22yadTMG
)02–10.5(01
)01–36.2(5
)65.3–40.1(2
)21–6.4(7
)79.9–35.3(6
)01–70.4(7
)02–64.9(41
)61–92.7(11
)53–71(42
)02–90.9(31
1yad/22yadRMG
)1291–006(4701
)6731–134(077
)122–77(131
)6631–616(719
)9001–914(056
)402–211(151
)887–294(226
)626–973(784
)275–083(664
)783–452(413
34yadTMG
)232–27(921
)661–15(29
)02–32.6(11
)961–96(801
)541–45(98
)83–12(82
)741–19(511
)111–76(68
)301–16(08
)16–63(74
1yad/34yadRMG
64Dn
25Dn
91Dn
14Dn
63Dn
11Dn
13Dn
42Dn
22Dn
12Dn
retsoob-erP
)105–921(452
)762–67(241
)911–62(65
)524–031(532
)592–18(451
)151–25(98
)842–811(171
)842–601(261
)682–87(051
)891–94(99
663yadTMG
)27–51(33
)73–87.8(81
)11–22.2(5
)06–71(23
)64–21(32
)92–85.9(71
)34–02(92
)44–81(82
)74–31(52
)33–33.8(71
1yad/663yadRMG
04Dn
74Dn
71Dn
83Dn
23Dn
01Dn
92Dn
02Dn
02Dn
91Dn
retsoob-tsoP
)5619–0293(4995)9947–6343(6705)7043–7001(2581)4306–1732(3873)4865–1202(9833)4674–9341(8162)6776–2892(6944)3447–5182(7754)8191–439(9331)9952–4111(1071
783yadTMG
)3522–522(217
)0971–512(126
)424–45(151
)5021–942(845
)4411–002(874
)779–152(694
)1121–774(067
)9431–844(777
)043–151(622
)515–891(913
1yad/783yadRMG
)64–11(32
)36–71(33
)18–61(63
)13–88.8(71
)93–37.9(91
)26–41(03
)34–61(62
)15–51(82
)71–43.4(74.8
)33–98.6(51
663/783yadRMG
evitcepsorterehtderiuqernoitaloivsihT.retsoobehtfonoitartsinimdaehtgnidragernoitaloivlocotorpgniwolloftesatadlanigiroehtfosisylana-eramorfdeviredera663–1syadrofdetneserpataD*
.atadretsoob-tsopetubirtnoctondidetistnailpmoc-nonehtsatesatadlanigiroehtotdnopserrocretsoobehtrofdetneserpataD.tesatadlanigiroehtmorfatadetistnailpmoc-nonehtfolavomer
362 HumanVaccines&Immunotherapeutics Volume11Issue2
*)teslocotorp-rep(04:1(cid:1)retitnoitibihninoitanitulggamehhtiwstcejbusfo)lavretniecnedfinoc%59dnaegatnecrep(rebmuN.3elbaT
4trohoC
3trohoC
2trohoC
1trohoC
)shtnom11–6(
)sraey3<–1(
)sraey8–3(
)sraey71–9(
gm5.7
gm57.3
gm51
gm5.7
gm57.3
gm51
gm5.7
gm57.3
gm5.7
gm57.3
95FMllufC
95FMflahC
95FMonC
95FMllufC
95FMflahC
95FMonC
95FMllufC
95FMflahC
95FMllufC
95FMflahC
)45Dn(
)85Dn(
)52Dn(
)35Dn(
)15Dn(
)13Dn(
)06Dn(
)85Dn(
)17Dn(
)27Dn(
)71(9
)71(01
)02(5
)31(7
)21(6
)0(0
)2(1
)0(0
)3(2
)6(4
1yaD
)92–8(
)92–9(
)14–7(
)52–5(
)42–4(
)11–0(
)9–240.0(
)6–0(
)01–0(
)41–2(
y)47(04
)75(33
)23(8
y)77(14
y)37(73
)56(02
y)38(05
y)97(64
y)09(46
y)28(95
22yaD
)58–06(
)07–34(
)45–51(
)88–46(
)48–85(
)18–54(
)29–17(
)98–76(
)69–18(
)09–17(
y)001(45
y)001(85
y)88(22
y)001(35
y)001(15
y)79(03
y)001(06
y)001(85
y)001(17
y)001(27
34yaD
)001–39(
)001–49(
)79–96(
)001–39(
)001–39(
)001–38(
)001–49(
)001–49(
)001–59(
)001–59(
64Dn
25=n
91Dn
14Dn
63Dn
11Dn
13Dn
42Dn
22Dn
12Dn
retsoob-erP
y)001(64
y)49(94
y)47(41
y)001(14
y)001(63
y)19(01
y)001(13
y)001(42
y)59(12
y)68(81
663yaD
)001–29(
)99–48(
)19–94(
)001–19(
)001–09(
)001–95(
)001–98(
)001–68(
)001–77(
)79–46(
04Dn
74Dn
71Dn
83Dn
23Dn
01Dn
92Dn
02Dn
02Dn
91Dn
retsoob-tsoP
y)001(04
y)001(74
y)001(71
y)001(83
y)001(23
y)001(01
y)001(92
y)001(02
y)001(02
y)001(91
783yaD
)001–19(
)001–29(
)001–08(
)001–19(
)001–98(
)001–96(
)001–88(
)001–38(
)001–38(
)001–28(
evitcepsorterehtderiuqernoitaloivsihT.retsoobehtfonoitartsinimdaehtgnidragernoitaloivlocotorpgniwolloftesatadlanigiroehtfosisylana-eramorfdeviredera663–1syadrofdetneserpataD* .atadretsoob-tsopetubirtnoctondidetistnailpmoc-nonehtsatesatadlanigiroehtotdnopserrocretsoobehtrofdetneserpataD.tesatadlanigiroehtmorfatadetistnailpmoc-nonehtfolavomer
.%07>si04:1(cid:1)retitnoitibihninoitanitulggamehgniveihcastcejbusfoegatnecrePy
www.tandfonline.com HumanVaccines&Immunotherapeutics 363
*)teslocotorp-rep(noitibihninoitanitulggamehniesaercnitnacfiingisronoisrevnocoresdeveihcaohwstcejbusfo)lavretniecnedfinoc%59dnaegatnecrep(rebmuN.4elbaT
4trohoC
3trohoC
2trohoC
1trohoC
)shtnom11–6(
)sraey3<–1(
)sraey8–3(
)sraey71–9(
gm5.7
gm57.3
gm51
gm5.7
gm57.3
gm51
gm5.7
gm57.3
gm5.7
gm57.3
MllufC
MflahC
MonC
MllufC
MflahC
MonC
MllufC
MflahC
MllufC
MflahC
95F
95F
95F
95F
95F
95F
95F
95F
95F
95F
)45Dn(
)85Dn(
)52Dn(
)35Dn(
)15Dn(
)13Dn(
)06Dn(
)85Dn(
)17Dn(
)27Dn(
)58–06(y)47(04
)07–34(y)75(33
)45–51()23(8
)88–46(y)77(14
)48–85(y)37(73
)18–54(y)56(02
)29–17(y)38(05
)98–76(y)97(64
)59–97(y)98(36
)78–66(y)87(65
22yaD
)001–39(y)001(45)001–19(y)89(75
)59–46(y)48(12
)001–39(y)001(35)001–09(y)89(05
)001–38(y)79(03
)001–49(y)001(06)001–49(y)001(85)001–59(y)001(17)001–39(y)99(17
34yaD
64Dn
25Dn
91Dn
14Dn
63Dn
11Dn
13Dn
42Dn
22Dn
12Dn
retsoob-erP
)89–97()19(24
)29–07()38(34
)17–42()74(9
)79–77()09(73
)89–87()29(33
)001–95()19(01
)001–98()001(13
)001–68()001(42
)001–77()59(12
)79–46()68(81
663yaD
)1yadmorf(
04Dn
74Dn
71Dn
83Dn
23Dn
01Dn
92Dn
02Dn
02Dn
91Dn
retsoob-tsoP
)001–19()001(04
)001–98()89(64
)001–08()001(71
)001–19()001(83
)001–98()001(23
)001–96()001(01
)001–88()001(92
)001–38()001(02
)001–38()001(02
)001–28()001(91
783yaD
)1yadmorf(
)79–67(y)09(63
)49–27(y)58(04
)001–08(y)001(71
)99–28(y)59(63
)99–97(y)49(03
)001–96(y)001(01)001–88(y)001(92
)001–57(y)59(91
)49–65(y)08(61
)99–76(y)98(71
783yaD
)663yadmorf(
evitcepsorterehtderiuqernoitaloivsihT.retsoobehtfonoitartsinimdaehtgnidragernoitaloivlocotorpgniwolloftesatadlanigiroehtfosisylana-eramorfdeviredera663–1syadrofdetneserpataD* .atadretsoob-tsopetubirtnoctondidetistnailpmoc-nonehtsatesatadlanigiroehtotdnopserrocretsoobehtrofdetneserpataD.tesatadlanigiroehtmorfatadetistnailpmoc-nonehtfolavomer
.%04(cid:1)sinoitibihninoitanitulggamehniesaercnitnacfiingisronoisrevnocoresgniveihcastcejbusfoegatnecrePy
364 HumanVaccines&Immunotherapeutics Volume11Issue2
)teslocotorp-rep(033:1(cid:1)noitibihninoitanitulggamehhtiwstcejbusfo)lavretniecnedfinoc%59dnaegatnecrep(rebmuN.5elbaT
4trohoC
3trohoC
2trohoC
1trohoC
)shtnom11–6(
)sraey3<–1(
)sraey8–3(
)sraey71–9(
gm5.7
gm57.3
gm51
gm5.7
gm57.3
gm51
gm5.7
gm57.3
gm5.7
gm57.3
95FMllufC
95FMflahC
95FMonC
95FMllufC
95FMflahC
95FMonC
95FMllufC
95FMflahC
95FMllufC
95FMflahC
)45Dn(
)85Dn(
)52Dn(
)35Dn(
)15Dn(
)13Dn(
)06Dn(
)85Dn(
)17Dn(
)27Dn(
)81–2()7(4
)71–2()7(4
)13–3()21(3
)81–2()8(4
)61–1()6(3
)11–0()0(0
)6–0()0(0
)6–0()0(0
)5–0()0(0
)7–530.0()1(1
1yaD
)13–9()91(01
)13–01()91(11
)14–7()02(5
)52–5()31(7
)42–4()21(6
)12–1()6(2
)21–0()3(2
)21–0()3(2
)92–01()81(31
)42–7()41(01
22yaD
)29–17()38(54
)28–75()17(14
)54–9()42(6
)99–48()49(05
)68–06()57(83
)62–2()01(3
)08–55()86(14
)67–05()46(73
)16–73()94(53
)36–93()15(73
34yaD
64Dn
25Dn
91Dn
14Dn
63Dn
11Dn
13Dn
42Dn
22Dn
12Dn
-erP
retsoob
)12(4
)04–21()42(01
)92–5()41(5
)82–0()0(0
)03–4()31(4
)12–0()4(1
)54–8()32(5
)24–5()91(4
663yaD
)25–32()73(71
)93–41()52(31
)64–6(
04Dn
74Dn
71Dn
83Dn
23Dn
01Dn
92Dn
02Dn
02Dn
91Dn
-tsoP
retsoob
)001–19()001(04
)001–29()001(74
)001–17()49(61
)001–19()001(83
)99–97()49(03
)001–55()09(9
)001–88()001(92
)001–38()001(02
)001–57()59(91
)001–47()59(81
783yaD
www.tandfonline.com HumanVaccines&Immunotherapeutics 365
Table6.Summaryofimmunogenicitydatabasedonthemicroneutralization(MN)assay(per-protocolset)*
3.75mgChalfMF59 7.5mgCfullMF59
Cohort1(9–17years) (nD72) (nD71)
GMTsandGMRs Day1 5.84(5.06–6.74) 5.21(4.53–5.99)
(95%CI) Day22 84(61–116) 150(109–205)
Day22overday1 14(11–20) 29(21–39)
Day43 323(260–402) 557(452–687)
Day43overday1 55(44–70) 107(85–134)
Pre-booster nD21 nD22
Day366 63(35–112) 66(38–112)
Day366overday1 11(6.66–20) 12(7.27–20)
Post-booster nD19 nD20
Day387 1239(616–2495) 1351(746–2446)
Day387overday1 227(98–526) 245(120–499)
Day387overday366 16(5.75–43) 20(8.37–46)
Subjects(n,%)withMN nD72 nD71
titers(cid:1)1:40 Day1 3(4)(1–12) 0(0)(0–5)
(95%CI) Day22 55(76)(65–86) 67(94)(86–98)
Day43 72(100)(95–100) 71(100)(95–100)
Pre-booster nD21 nD22
Day366 15(71)(48–89) 18(82)(60–95)
Post-booster nD19 nD20
Day387 (95)(74–100) 20(100)(83–100)
Subjects(n,%)withan nD72 nD71
atleast4-fold Day22 62(86)(76–93) 68(96)(88–99)
increaseinMN Day43 71(99)(93–100) 71(100)(95–100)
titers(95%CI)
Pre-booster nD21 nD22
Day366today1 17(81)(58–95) 19(86)(65–97)
Post-booster nD19 nD20
Day387today1 (95)(74–100) 20(100)(83–100)
Day387today366 (89)(67–99) (85)(62–97)
Cohort2(3–8years) 3.75mgChalfMF59 7.5mgCfullMF59 15mgCnoMF59
(nD58) (nD60) (nD31)
GMTsandGMRs Day1 5.08(4.59–5.62) 5.16(4.69–5.68) 5.37(4.76–6.07)
(95%CI) Day22 50(31–82) 64(41–100) 33(19–60)
Day22overday1 9.93(6.16–16) 12(7.89–19) 6.22(3.51–11)
Day43 536(400–719) 668(507–879) 160(113–228)
Day43overday1 106(78–144) 129(97–173) 30(21–43)
Pre-booster nD24 nD31 nD11
Day366 56(33–93) 100(64–156) 40(21–76)
Day366overday1 10(6.13–18) 19(12–29) 7.49(3.89–14)
Post-booster nD20 nD29 nD10
Day387 4190(2442–7188) 4411(2797–6956) 2232(1149–4338)
Day387overday1 775(416–1444) 817(483–1381) 416(193–895)
Day387overday366 75(43–132) 45(28–72) 53(27–106)
Subjects(n,%)withMN nD58 nD60 nD31
titers(cid:1)1:40 Day1 0(0)(0–6) 1(2)(0.042–9) 0(0)(0–11)
(95%CI) Day22 35(60)(47–73) 44(73)(60–84) 18(58)(39–75)
Day43 57(98)(91–100) 60(100)(94–100) 26(84)(66–95)
Pre-booster nD24 nD31 nD11
Day366 17(71)(49–87) 28(90)(74–98) 6(55)(23–83)
Post-booster nD20 nD29 nD10
Day387 20(100)(83–100) 29(100)(88–100) 10(100)(69–100)
Subjects(n,%)withan nD58 nD60 nD31
atleast4-fold Day22 46(79)(67–89) 49(82)(70–90) 17(55)(36–73)
increaseinMN Day43 58(100)(94–100) 60(100)(94–100) 30(97)(83–100)
titers(95%CI)
Pre-booster nD24 nD31 nD11
Day366today1 22(92)(73–99) 30(97)(83–100) 8(73)(39–94)
Post-booster nD20 nD29 nD10
Day387today1 20(100)(83–100) 29(100)(88–100) 10(100)(69–100)
Day387today366 20(100)(83–100) 29(100)(88–100) 10(100)(69–100)
(continuedonnextpage)
366 HumanVaccines&Immunotherapeutics Volume11Issue2
Table6.Summaryofimmunogenicitydatabasedonthemicroneutralization(MN)assay(per-protocolset)*(Continued)
Cohort3(12–35months) 3.75mgChalfMF59 7.5mgCfullMF59 15mgCnoMF59
(nD51) (nD54) (nD25)
GMTsandGMRs(95%CI) Day1 5.05(2.88–8.88) 6.14(3.68–10) 8.71(4.45–17)
Day22 21(8.17–52) 32(14–73) 14(4.74–43)
Day22overday1 4.07(2.19–7.56) 5.15(2.94–9.02) 1.63(0.78–3.42)
Day43 580(352–957) 764(486–1203) 100(55–181)
Day43overday1 115(76–174) 125(85–182) 11(6.96–19)
Pre-booster nD36 nD41 nD19
Day366 175(82–370) 292(147–579) 71(30–171)
Day366overday1 26(13–53) 42(22–79) 5.98(2.64–14)
Post-booster nD31 nD38 nD17
Day387 5645(3371–9452) 6505(4091–10343) 2983(1628–5464)
Day387overday1 735(308–1754) 998(456–2182) 232(83–643)
Day387overday366 28(12–62) 23(11–48) 46(18–119)
Subjects(n,%)withMNtiters(cid:1)1:40(95%CI) nD51 nD54 nD25
Day1 4(8)(2–19) 6(11)(4–23) 5(20)(7–41)
Day22 24(47)(33–62) 30(56)(41–69) 7(28)(12–49)
Day43 51(100)(93–100) 54(100)(93–100) 20(80)(59–93)
Pre-booster nD36 nD41 nD19
Day366 34(94)(81–99) 40(98)(87–100) 13(68)(43–87)
Post-booster nD31 nD38 nD17
Day387 31(100)(89–100) 38(100)(91–100) 17(100)(80–100)
Subjects(n,%)withanatleast4-foldincreaseinMNtiters(95%CI) nD51 nD54 nD25
Day22 30(59)(44–72) 40(74)(60–85) 9(36)(18–57)
Day43 51(100)(93–100) 54(100)(93–100) 22(88)(69–97)
Pre-booster nD36 nD41 nD19
Day366today1 34(94)(81–99) 41(100)(91–100) 9(47)(24–71)
Post-booster nD31 nD38 nD17
Day387today1 31(100)(89–100) 38(100)(91–100) 17(100)(80–100)
Day387today366 (90)(74–98) (87)(72–96) (94)(71–100)
Cohort4(6–11months) 3.75mgChalfMF59 7.5mgCfullMF59
(nD58) (nD54)
GMTsandGMRs(95%CI) Day1 8.78(3.34–23) 8.59(3.25–23)
Day22 25(5.77–105) 46(11–197)
Day22overday1 2.8(1.32–5.97) 5.36(2.51–11)
Day43 759(387–1486) 1039(529–2038)
Day43overday1 86(49–153) 121(68–214)
Pre-booster nD52 nD46
Day366 195(105–364) 388(198–758)
Day366overday1 24(12–50) 50(23–110)
Post-booster nD47 nD39
Day387 9302(6597–13118) 9482(6492–13849)
Day387overday1 1097(354–3397) 1122(323–3899)
Day387overday366 43(22–84) 23(11–48)
Subjects(n,%)withMNtiters(cid:1)1:40(95%CI) nD58 nD54
Day1 10(17)(9–29) 9(17)(8–29)
Day22 17(29)(18–43) 25(46)(33–60)
Day43 58(100)(94–100) 54(100)(93–100)
Pre-booster nD52 nD46
Day366 50(96)(87–100) 46(100)(92–100)
Post-booster nD47 nD39
Day387 47(100)(92–100) 39(100)(91–100)
Subjects(n,%)withanatleast4-foldincreaseinMNtiters(95%CI) nD58 nD54
Day22 25(43)(30–57) 32(59)(45–72)
Day43 58(100)(94–100) 54(100)(93–100)
Pre-booster nD52 nD46
Day366today1 47(90)(79–97) 43(93)(82–99)
Post-booster nD47 nD39
Day387today1 (98)(89–100) (97)(87–100)
Day387today366 (83)(69–92) (79)(64–91)
*Datapresentedfordays1–366arederivedfromare-analysisoftheoriginaldatasetfollowingprotocolviolationregardingtheadministrationofthebooster.Thisviolation
requiredtheretrospectiveremovalofthenon-compliantsitedatafromtheoriginaldataset.Datapresentedfortheboostercorrespondtotheoriginaldatasetasthenon-
compliantsitedidnotcontributepost-boosterdata.CI,confidenceinterval;GMR,geometricmeanratio;GMT,geometricmeantiter.
www.tandfonline.com HumanVaccines&Immunotherapeutics 367
)noitalupopytefas(noitaniccavhcaeretfasyad7nihtiwnoitcaerlacol)mm001>/erevesdna(ynahtiwstcejbusfo)%(srebmuN.7elbaT
retsooB
dnoceS
tsriF
noitaniccav
noitaniccav
noitaniccav
gm57.3
gm5.7
95FMflahC
95FMllufC
tnelavirt!
tnelavirt!
lanosaes
gm5.7
gm57.3
gm5.7
gm57.3
95FMlanosaes
eniccav95FM
95FMllufC
95FMflahC
95FMllufC
95FMflahC
1trohoC
)42Dn(eniccav
)32Dn(
)87Dn(
)77Dn(
)97Dn(
)97Dn(
)sraey71–9(
0
)9(2
)3(2
)4(3
)6(5
)4(3
ynA
sisomyhccE
0
0
0
0
0
0
mm001>
)31(3
)9(2
)31(01
)5(4
)9(7
)8(6
ynA
amehtyrE
0
0
0
0
0
0
mm001>
)31(3
)22(5
)6(5
)9(7
)51(21
)11(9
ynA
noitarudnI
0
0
0
0
0
0
mm001>
)71(4
0
)9(7
)5(4
)31(01
)6(5
ynA
gnillewS
0
0
0
0
0
0
mm001>
)97(91
)47(71
)55(34
)55(24
)28(56
)86(45
ynA
niaP
)8(2
)31(3
)1(1
0
)1(1
0
ereveS
noitaniccavlanosaesdnoceS
noitaniccavretsooB
noitaniccavdnoceS
noitaniccavtsriF
)sraey8–3(2trohoC
Cgm51
Cgm5.7
gm57.3
95FMonCgm51
Cgm5.7
gm57.3
95FMonCgm51
95FMllufCgm5.7
Cgm57.3
95FMonCgm51
Cgm5.7
Cgm57.3
!95FMon
!95FMlluf
!95FMflahC
tnelavirt!
!95FMlluf
!95FMflahC
)63Dn(
)07Dn(
95FMflah
)93Dn(
95FMlluf
95FMflah
tnelavirt£2
tnelavirt£2
tnelavirt£2
lanosaes
tnelavirt
tnelavirt
)07Dn(
)27Dn(
)07Dn(
lanosaes
95FMlanosaes
95FMlanosaes
eniccav95FM
95FMlanosaes
95FMlanosaes
eniccav95FM
eniccav
)22Dn(eniccav
)41Dn(
eniccav
)03Dn(eniccav
)11Dn(
)62Dn(
)53Dn(
0
)4(1
0
0
)3(1
)3(1
)11(4
)7(5
)9(6
)81(7
)8(6
)6(4
ynA
sisomyhccE
0
0
0
0
0
0
0
0
0
0
0
0
mm001>
0
)32(6
)81(4
0
)41(5
)72(8
)8(3
)02(41
)01(7
)81(7
)91(41
)61(11
ynA
amehtyrE
0
0
0
0
0
0
0
0
0
0
0
0
mm001>
0
)72(7
)81(4
0
)41(5
)31(4
)8(3
)41(01
)6(4
)8(3
)51(11
)9(6
ynA
noitarudnI
0
0
0
0
0
0
0
0
0
0
0
0
mm001>
)9(1
)91(5
)81(4
)7(1
)41(5
)01(3
)6(2
)7(5
)7(5
)5(2
)01(7
)7(5
ynA
gnillewS
0
0
0
0
0
0
0
0
0
0
0
0
mm001>
)46(7
)05(31
)95(31
)46(9
)96(42
)77(32
)82(01
)34(03
)83(96/62
)63(41
)64(33
)34(03
ynA
niaP
0
)4(1
0
0
)3(1
)3(1
0
0
)1(96/1
0
)3(2
)1(1
ereveS
)egaptxennodeunitnoc(
368 HumanVaccines&Immunotherapeutics Volume11Issue2
noitaniccavlanosaesdnoceS
noitaniccavretsoobtsriF
noitaniccavdnoceS
noitaniccavtsriF
)sraey3<–1(3trohoC
Cgm51
Cgm5.7
gm57.3
Cgm51
Cgm5.7
gm57.3
95FMonCgm51
Cgm5.7
Cgm57.3
95FMonCgm51
Cgm5.7
Cgm57.3
!95FMon
!95FMlluf
!95FMflahC
!95FMon
!95FMlluf
!95FMflahC
)92Dn(
95FMlluf
95FMflah
)33Dn(
95FMlluf
95FMflah
tnelavirt£2
tnelavirt£2
tnelavirt£2
tnelavirt
tnelavirt
tnelavirt
)17Dn(
)46Dn(
)37Dn(
)56Dn(
lanosaes
95FMlanosaes
95FMlanosaes
95FMlanosaes
95FMlanosaes
95FMlanosaes
eniccav95FM
eniccav
eniccav
eniccav
eniccav
)24Dn(eniccav
)71Dn
)54Dn(
)63Dn(
)12Dn
)15Dn(
)6(1
)2(1
0
0
)01(5
)5(2
)7(2
)7(5
)2(1
)51(5
)11(8
)5(3
ynA
)mm(sisomyhccE
0
0
0
0
0
0
0
0
0
0
0
0
mm001>
)21(2
)22(01
)82(01
)91(4
)52(31
)41(6
)41(4
)51(11
)9(6
)81(6
)61(21
)21(8
ynA
)mm(amehtyrE
0
0
0
0
0
0
0
)1(1
0
0
0
0
mm001>
)81(3
)81(8
)22(8
)41(3
)41(7
)01(4
)7(2
)6(4
)3(2
)9(3
)41(01
)9(6
ynA
)mm(noitarudnI
0
0
0
0
0
0
0
0
0
0
0
0
mm001>
)21(2
)61(7
)91(7
)5(1
)8(4
)41(6
)3(1
)6(4
)2(1
)6(2
)5(4
)2(1
ynA
)mm(gnillewS
0
0
0
0
0
0
0
0
0
0
)1(1
0
mm001>
)42(4
)42(11
)22(8
)33(7
)53(81
)91(8
)13(9
)03(12
)8(5
)03(01
)14(03
)11(7
ynA
ssenredneT
)6(1
0
0
0
0
)2(1
0
)1(1
0
)3(1
)4(3
0
nehwdeirC bmildetcejni devomsaw
noitaniccavretsooB
noitaniccavretsooB
noitaniccavdnoceS
noitaniccavtsriF
)shtnom11–6(4trohoC
gm5.7
gm57.3
gm5.7
Cgm57.3
Cgm5.7
95FMflahCgm57.3
Cgm5.7
Cgm57.3
!95FMllufC
!95FMflahC
!95FMllufC
!95FMflah
95FMlluf
)17Dn(
95FMlluf
95FMflah
tnelavirt£2
tnelavirt£2
tnelavirt
tnelavirt
)07Dn(
)47Dn(
)57Dn(
95FMlanosaes
95FMlanosaes
95FMlanosaes
lanosaes
)06Dn(eniccav
)36Dn(eniccav
)16Dn(eniccav
95FM eniccav )76Dn(
)2(1
)2(1
)2(1
)1(1
0
)4(3
0
)3(2
ynA
)mm(sisomyhccE
0
0
0
0
0
0
0
0
mm001>
)01(6
)01(6
)51(9
)7(5
)4(3
)31(9
)7(5
)8(6
ynA
)mm(amehtyrE
0
0
)2(1
0
0
0
0
0
mm001>
)8(5
)01(6
)7(4
)7(5
)01(7
)4(3
)4(3
)5(4
ynA
)mm(noitarudnI
0
0
0
0
0
0
0
0
mm001>
)5(3
)5(3
)8(5
)1(1
0
)1(1
0
0
ynA
)mm(gnillewS
0
0
0
0
0
0
0
0
mm001>
)22(31
)22(41
)13(91
)61(11
)62(81
)71(21
)32(71
)21(9
ynA
ssenredneT
)5(3
)3(2
)3(2
)3(2
)1(1
0
)3(2
0
nehwdeirC
sawbmildetcejni
devom
www.tandfonline.com HumanVaccines&Immunotherapeutics 369
)noitalupopytefas(noitaniccavhcaeretfad7nihtiwnoitcaercimetsys)erevesdna(ynahtiwstcejbusfo)%(srebmuN.8elbaT
noitaniccavretsooB
noitaniccavdnoceS
noitaniccavtsriF
C gm57.3
C gm5.7
!95FMflah
!95FMlluf
tnelavirt
tnelavirt
lanosaes
lanosaes
95FM
C gm57.3
C gm57.3
Cgm5.7
Cgm57.3
eniccav95FM
eniccav
95FMflah
95FMflah
95FMlluf
95FMflah
)42=n(
)32Dn(
)87Dn(
)77Dn(
)97Dn(
)97Dn(
)sraey71–9(1trohoC
)4(1
)4(1
)9(7
)3(2
)4(3
)1(1
ynA
sllihC
0
0
0
0
0
0
ereveS
)31(3
)22(5
)01(8
)8(6
)11(9
)8(6
ynA
esialaM
0
0
0
0
0
)1(1
ereveS
)33(8
)03(7
)01(8
)01(8
)02(61
)02(61
ynA
aiglayM
0
0
0
0
0
)1(1
ereveS
)8(2
)4(1
)5(4
)8(6
)01(8
)8(6
ynA
aiglarhtrA
0
0
0
0
0
0
ereveS
)12(5
)22(5
)31(01
)41(11
)92(32
)32(81
ynA
ehcadaeH
0
)4(1
0
)3(2
)3(2
)3(2
ereveS
)8(2
)9(2
0
)1(1
)4(3
)5(4
ynA
gnitaewS
0
0
0
0
0
0
ereveS
)8(2
)71(4
)41(11
)61(21
)72(12
)02(61
ynA
eugitaF
0
)4(1
)1(1
)4(3
)1(1
)1(1
ereveS
)8(2
)71(4
)4(3
)5(4
)8(6
)6(5
ynA
aesuaN
)4(1
0
0
0
0
)1(1
ereveS
0
)4(1
)1(1
)3(2
0
)1(1
seY
)C(cid:2)83(cid:1)(reveF
rehtO
)001(42
)69(22
)99(77
)79(57
)001(97
)99(87
C(cid:2)0.83<
)C(cid:2)(erutarepmeT
0
0
0
0
0
0
C(cid:2)0.04(cid:1)
)8(2
)31(3
)4(3
)4(3
0
)3(2
seY
emohdeyatS
)31(3
)71(4
)6(5
)6(5
)9(7
)9(7
seY
citerypitna/ciseglanA desusnoitacidem
noitaniccavlanosaesdnoceS
noitaniccavretsooB
noitaniccavdnoceS
noitaniccavtsriF
)sraey8–3(2trohoC
C gm51
C gm5.7
C
gm57.3
C gm51
C gm5.7
C
gm57.3
C gm51
C gm5.7
C gm57.3
C gm51
C gm5.7
Cgm57.3
!95FMon
!95FMlluf
!95FMflah
!95FMon
!95FMlluf
!95FMflah
95FMon
95FMlluf
95FMflah
95FMon
95FMlluf
95FMflah
tnelavirt£2
tnelavirt£2
tnelavirt£2
tnelavirt
tnelavirt
tnelavirt
)63Dn(
)07Dn(
)96Dn(
)93Dn(
)27Dn(
)07Dn(
lanosaes
lanosaes
lanosaes
lanosaes
lanosaes
lanosaes
95FM
95FM
95FM
95FM
95FM
95FM
eniccav
eniccav
eniccav
eniccav
eniccav
eniccav
)11Dn(
)62Dn(
)22Dn(
)41Dn(
)53Dn(
)03Dn(
0
)4(1
0
0
)41(5
)01(3
)6(2
)7(5
)1(1
0
)3(2
)4(3
ynA
sllihC
0
0
0
0
)6(2
0
0
0
0
0
0
0
ereveS
)9(1
)8(2
)5(1
0
)13(11
)72(8
)11(4
)6(4
)6(4
)51(6
)4(3
)31(9
ynA
esialaM
0
0
)5(1
0
)3(1
0
0
0
0
0
)3(2
)3(2
ereveS
)9(1
)8(2
)5(1
)92(4
)62(9
)31(4
)6(2
)11(8
)3(2
)5(2
)4(3
)7(5
ynA
aiglayM
0
0
0
0
)3(1
0
0
0
0
0
0
0
ereveS
)egaptxennodeunitnoc(
370 HumanVaccines&Immunotherapeutics Volume11Issue2
)deunitnoC()noitalupopytefas(noitaniccavhcaeretfad7nihtiwnoitcaercimetsys)erevesdna(ynahtiwstcejbusfo)%(srebmuN.8elbaT
)9(1
)8(2
)5(1
)41(2
)41(5
)71(5
)6(2
)4(3
)4(3
0
)4(3
)3(2
ynA
aiglarhtrA
0
0
0
0
0
0
0
0
0
0
0
0
ereveS
)9(1
)21(3
)41(3
)7(1
)13(11
)33(01
)71(6
)6(4
)1(1
)3(1
)7(5
)01(7
ynA
ehcadaeH
0
0
0
0
)3(1
0
0
0
0
0
)1(1
)3(2
ereveS
0
)4(1
0
0
)9(3
)7(2
0
0
0
0
)1(1
)1(1
ynA
gnitaewS
0
0
0
0
)3(1
0
0
0
0
0
0
0
ereveS
)81(2
)32(6
)41(3
)7(1
)92(01
)32(7
)41(5
)41(01
)21(8
)81(7
)12(51
)42(71
ynA
eugitaF
0
0
0
0
)3(1
0
0
0
0
0
)4(3
)3(2
ereveS
)9(1
)8(2
)5(1
)7(1
)71(6
)31(4
)6(2
)1(1
)4(3
)5(2
)7(5
)3(2
ynA
aesuaN
0
0
)5(1
0
)3(1
0
0
0
0
0
)1(1
)1(1
ereveS
)9(1
)8(2
)5(1
0
)32(8
0
)8(3
)4(3
)4(3
0
)6(4
)01(7
seY
)C(cid:2)83(cid:1)(reveF
rehtO
)19(01
)29(42
)59(12
)001(41
)77(72
)001(03
)29(33
)69(76
)69(66
)001(93
)49(86
)09(36
C(cid:2)0.83<
erutarepmeT
0
0
0
0
0
0
0
0
0
0
0
0
C(cid:2)0.04(cid:1)
0
0
)5(1
0
)92(01
)01(3
)8(3
)9(6
)1(1
0
)41(01
)7(5
seY
emohdeyatS
)9(1
)32(6
)9(2
)7(1
)32(8
)31(4
)6(2
)01(7
)3(2
)01(4
)51(11
)31(9
seY
desusnoitacidemciterypitna/ciseglanA
noitaniccavlanosaesdnoceS
noitaniccavretsooB
noitaniccavdnoceS
noitaniccavtsriF
)sraey3<–1(3trohoC
C gm51
C gm5.7
C
gm57.3
C gm51
C gm5.7
C
gm57.3
C gm51
C gm5.7
C gm57.3
C gm51
C gm5.7
Cgm57.3
!95FMon
!95FMlluf
!95FMflah
!95FMon
!95FMlluf
!95FMflah
95FMon
95FMlluf
95FMflah
95FMon
95FMlluf
95FMflah
tnelavirt£2
tnelavirt£2
tnelavirt£2
tnelavirt
tnelavirt
tnelavirt
)92Dn(
)17Dn(
)46Dn(
)33Dn(
)37Dn(
)56Dn(
lanosaes
lanosaes
lanosaes
lanosaes
lanosaes
lanosaes
95FM
95FM
95FM
95FM
95FM
95FM
eniccav
eniccav
eniccav
eniccav
eniccav
eniccav
)71=n(
)54Dn(
)63Dn(
)12Dn(
)15Dn(
)24Dn(
)6(1
)2(1
)3(1
)5(1
)21(6
)12(9
)41(4
)81(31
)71(11
)12(7
)23(32
)22(41
tneserP
ssenipeelS
0
)7(3
)8(3
)5(1
)8(4
)41(6
)41(4
)41(01
)61(01
)81(6
)32(71
)32(51
tneserP
aehrraiD
0
)2(1
)3(1
0
)4(2
)2(1
)3(1
)11(8
)8(5
)6(2
)51(11
)11(7
tneserP
gnitimoV
)81(3
)7(3
)6(2
)41(3
)6(3
)21(5
)7(2
)8(6
)41(9
)51(5
)32(71
)62(71
tneserP
ytilibatirrI
)6(1
)4(2
)8(3
)5(1
)8(4
)21(5
)41(4
)51(11
)91(21
)21(4
)52(81
)22(41
tneserP
stibahgnitaeniegnahC
0
0
)3(1
0
)6(3
)2(1
)3(1
)6(4
)6(4
)3(1
)3(2
)5(3
tneserP
gnirevihS
)6(1
)7(3
)3(1
)5(1
)8(4
)7(3
)01(3
)51(11
)71(11
)12(7
)03(22
)32(51
tneserP
gniyrclausunU
0
)9(4
)8(3
)01(2
)92(51
)41(6
)3(1
)01(7
)91(21
)21(4
)11(8
)21(8
seY
)C(cid:2)83(cid:1)(reveF
rehtO
)001(71
)19(14
)29(33
)09(91
)17(63
)68(63
)79(82
)09(46
)18(25
)88(92
)98(56
)88(75
C(cid:2)0.83<
erutarepmeT
0
0
0
)5(1
0
)2(1
0
)1(1
0
0
0
0
C(cid:2)0.04(cid:1)
0
0
)3(1
)01(2
)2(05/1
)21(14/5
)01(3
)3(2
)31(8
)6(23/2
)11(8
)9(6
seY
emohdeyatS
)6(1
)31(6
)8(3
)42(5
)92(51
)91(8
)82(8
)12(51
)82(81
)52(23/8
)92(12
)32(51
seY
desusnoitacidemciterypitnaciseglanA
)egaptxennodeunitnoc(
www.tandfonline.com HumanVaccines&Immunotherapeutics 371
)deunitnoC()noitalupopytefas(noitaniccavhcaeretfad7nihtiwnoitcaercimetsys)erevesdna(ynahtiwstcejbusfo)%(srebmuN.8elbaT
noitaniccavlanosaesdnoceS
noitaniccavretsooB
noitaniccavdnoceS
noitaniccavtsriF
)shtnom11–6(4trohoC
C gm5.7
C
gm57.3
C gm5.7
C
gm57.3
C gm5.7
C gm57.3
C gm5.7
Cgm57.3
!95FMlluf
!95FMflah
!95FMlluf
!95FMflah
95FMlluf
95FMflah
95FMlluf
95FMflah
tnelavirt£2
tnelavirt£2
tnelavirt
tnelavirt
)07Dn(
)17Dn(
)47Dn(
)57Dn(
lanosaes
lanosaes
lanosaes
lanosaes
95FM
95FM
95FM
95FM
eniccav
eniccav
eniccav
eniccav
)06Dn(
)36Dn(
)16Dn(
)76Dn(
)8(5
)5(3
)61(01
)7(5
)91(31
)41(01
)02(51
)61(21
tneserP
ssenipeelS
)21(7
)11(7
)01(6
)21(8
)92(02
)81(31
)03(22
)72(02
tneserP
aehrraiD
)3(2
)8(5
)2(1
)3(2
)41(01
)11(8
)51(11
)61(21
tneserP
gnitimoV
)3(2
)6(4
)01(6
)4(3
)9(6
)31(9
)51(11
)21(9
tneserP
ytilibatirrI
)8(5
)01(6
)11(7
)3(2
)71(21
)41(01
)82(12
)71(31
tneserP
stibahgnitaeniegnahC
)2(1
)3(2
)3(2
)4(3
)6(4
)3(2
)3(2
)4(3
tneserP
gnirevihS
)5(3
)31(8
)51(9
)6(4
)42(71
)12(51
)22(61
)72(02
tneserP
gniyrclausunU
)71(01
)11(7
)12(31
)31(9
)71(21
)01(7
)9(7
)9(7
seY
)C(cid:2)83(cid:1)(reveF
rehtO
)38(05
)98(65
)97(84
)78(85
)38(85
)09(46
)19(76
)19(86
C(cid:2)0.83<
erutarepmeT
0
0
0
)1(1
0
)1(1
)1(1
0
C(cid:2)0.04(cid:1)
)5(3
)3(2
)8(5
)7(5
)01(7
)01(7
)7(5
)11(8
seY
emohdeyatS
)81(11
)61(01
)13(91
)91(31
)42(71
)32(61
)82(12
)12(61
seY
desusnoitacidemciterypitna/ciseglanA
372 HumanVaccines&Immunotherapeutics Volume11Issue2
groups and cohorts. Within each cohort, the occurrence of >70% of children while 2 doses of the half-adjuvant formu-
local and systemic reactions was higher in the 7.5_fullMF59 lation were required to achieve the same result. On a practi-
groups than the 3.75_halfMF59 groups. Systemic reactions cal level, and considering cost effectiveness, administering 1
were reported by more subjects in the adjuvanted groups vaccine dose rather than 2 doses would be preferable. How-
than in the nonadjuvanted group in cohort 3, but there was ever, this approach would require commercial availability of
no clear difference in the occurrence of systemic reactions the 2 presentations (3.75_halfMF59 and 7.5_fullMF59)
between adjuvanted and non-adjuvanted groups in cohort 2. which, during the very hectic times of a pandemic, may not
There was lower reactogenicity in all cohorts following the be easy to achieve. A study conducted in children and adoles-
administration of the seasonal MF59 vaccine after one year. cents aged 6 months to 18 y found that a single 15 mg dose
Unsolicited adverse events (AEs) through day 43 were of A/H1N1 monovalent vaccine resulted in HI titers (cid:1)1:40
reported by 32–34% of subjects in cohort 1 and 35–36% of in >70% of those aged 9 to <18 years of age; however a sin-
cohort2,withhigherratesforcohort3(37–61%)andforcohort gle 7.5 or 15 mg dose did not achieve the same result in sub-
4 (63–64%). Nasopharyngitis, diarrhea, vomiting, eating disor- jects 6 months to 8 y of age.27 Together, these results suggest
der, and pyrexia were the most frequently reported unsolicited that the number and formulation of adjuvant vaccine doses
AEs for cohorts3 and4 that were considered possibly related to should be tailored to children’s age in order to achieve HI
vaccine. The rate of unsolicited AEs following booster vaccina- titers (cid:1)1:40.
tions waslow, ranging from5%in cohort1,7%cohort2,10% Our study established that the 3 CHMP criteria for immu-
cohort3,and24%ofsubjectsincohort4. nogenicity were met 3 weeks following administration of the
From day 1–546, 48 subjects experienced 65 serious AEs booster adjuvanted vaccine in the 4 cohorts across all vaccine
(SAEs),withhigherratesevidentforcohorts3and4.ASAEcon- groups. This was the case regardless of the priming formulation
sidered possibly related to vaccine was reported for 3 subjects: and irrespective of HI titers at day 366. However, one concern
multipleseizureepisodesatday98affectingonesubjectincohort with the CHMP criteria is that they are based on studies con-
1(7.5_fullMF59);vomitinginonesubjectincohort3,26dafter ducted inadultsandtheapplicabilityof thesecriteriaforstudies
the third vaccination (7.5_fullMF59); and febrile convulsion at in children is not clear. While we were conducting this study, a
day 10 in one subject in cohort 4 (3.75_halfMF59). Eight sub- separate study in 777 vaccine-na€ıve children aged 6–72 months
jects, 2 in each of the 4 cohorts (3.75_halfMF59 n D 4; 50 d following administration of 2 doses of MF59-adjuvanted
7.5_fullMF59 n D 2; 15_noMF59 n D 2), discontinued study seasonal vaccine was published.28 Findings from this study sug-
participation from day 1–546 due to at least one AE, with all gested that the conventional adult HI titer of (cid:1)1:40 is only
withdrawals occurring before administration of the booster. No associated with 22% protection in children aged 6–72
deathsoccurredduringthestudy. months.28 Notably, titers of 1:110, 1:215, 1:330, and 1:629
were associated with protection rates of 50%, 70%, 80%, and
90%, respectively. The investigators concluded that a titer of
Discussion 1:330 would have more favorable public health implications.
To address this, we conducted a post-hoc analysis to establish
Effective,well-toleratedA/H1N1vaccinesareneededforchil- the percentages of subjects achieving an HI titer (cid:1)1:330. We
dren, particularly those aged 6–12 months, who are at high risk observed that at day 43, 49–94% of subjects receiving the adju-
ofcontractingthevirusduetolackofprotectionandprimingof vanted vaccines achieved this titer, compared with only 10%
theimmune system by exposure to theinfluenza virus. Children and 24% of subjects in cohorts 2 and 3 following vaccination
also contribute to virus transmission to family members and the with the nonadjuvanted vaccines. Following the booster, (cid:1)90
community at large.5,6 Our results demonstrate that nonadju- % of subjects achieved an HI titer (cid:1)1:330, with no difference
vanted A/H1N1 vaccines are less immunogenic than adjuvanted between those subjects primed with adjuvanted or non-adju-
formulations for children. Low immunogenicity of nonadju- vanted vaccine.
vantedvaccinesinchildrenhasalsobeenobservedinotherstud- Allstudyvaccinesweresafeandwelltolerated,withthemajor-
ies;forexample,HItiters(cid:1)1:40wereobservedin45%and69% ityofsolicitedreactionsmildandself-limiting.Thesafetyprofile
ofsubjectsaged6–35monthsand3–9 years,respectively,follow- oftheadjuvantedvaccinewasgenerallysimilartothatofthenon-
ing a single dose of nonadjuvanted A/California/07/2009 vac- adjuvanted vaccine, including in subjects who received repeat
cine,comparedwithratesof95%and94%insubjectsaged18– doses of the adjuvanted formulation; in line with previous stud-
64yand(cid:1)65 years,respectively.26 ies, local reactogenicity washigher withtheadjuvanted formula-
Our study showed that one vaccination with tion, especially in older age groups.29 Furthermore, the safety
3.75_halfMF59 or 7.5_fullMF59 induced an HI titer of profileofthecell-derivedvaccinewassimilartothesafetyprofile
(cid:1)1:40 in >70 % of children and adolescents in the 1–<3 previously reported for an equivalent egg-derived vaccine.30
year, 3–8 year, and 9–17 y cohorts; however, 2 vaccinations Together, these findings support the acceptable safety profile of
with nonadjuvanted 15 mg A/H1N1 antigen were needed to the cell-derived halfMF59 and fullMF59 formulations when
achieve a similar response in the 1–<3 and 3–8 y cohorts. administered with 3.75 mg or 7.5 mg of A/H1N1 antigen to
Among children aged 6–11 months, 1 dose of the fully adju- childrenaged6monthsto17y
vanted vaccine was associated with an HI titer of (cid:1)1:40 in
www.tandfonline.com HumanVaccines&Immunotherapeutics 373
Our findings support the immunogenicity and acceptable Immunogenicityanalysis
safety of the cell-derived MF59-adjuvanted A/H1N1 influenza Blood samples were taken on day 1 prior to vaccination, on
vaccineinchildrenaged6monthsto17y. days22,43,and366followingthefirst vaccination,andonday
387 (3 weeks after the booster). Immunogenicity was evaluated
by homologous (A/California/7/2009) H1N1 strain-specific HI
andMNassays.Immunogenicitymeasureswere:1)GMTforHI
Methods
andMNfortheprimaryvaccineandforthebooster;2)GMRof
HI and MN; 3) percentage of subjects achieving seroconversion
Studydesignandobjectives
(HI(cid:1)1:40forsubjectsnegativeatbaseline[HI<1:10]),orasig-
This randomized, single-blind, dose-ranging study was con-
nificant increase in HI (minimum 4-fold increase in HI titer for
ducted between 2009 and 2011 at 8 centers in Germany, 2 in
subjects positive at baseline); 4) percentage of subjects with a
Belgium, 2 in the Dominican Republic, and one in the Nether-
MNtiter(cid:1)1:40,1:80,and1:160;5)percentageofsubjectswith
lands. The protocol was approved by the Institutional Review
anHItiter(cid:1)1:40;and6)percentageofsubjectsachievingamin-
BoardorEthicsCommitteeateachcenterandthestudywascon-
imum 4-fold increase in MN titer. Following publication of HI
ducted in accordance with the principles of the Declaration of
antibody titers necessary for protection for inactivated influenza
Helsinki and Good Clinical Practice. Written informed consent
vaccinesinchildren,afurtheranalysiswasconductedtoevaluate
was obtained from each subject or their legal guardians before
thepercentageofsubjectswithanHItiter(cid:1)1:330.28
enrollment.ThestudywasregisteredwiththeNationalInstitutes
ofHealthdatabase,ClinicalTrials.gov(NCT00971100).
Safetyanalysis
Theprimarystudyobjectivewastoidentifythepreferredvac-
Safetyreactionswerecollectedondiarycardsandreviewedat
cineformulation(withorwithoutMF59),dosageofantigenand
each follow-up visit. The safety analysis included the number of
adjuvant, and schedule (1 or 2 administrations) of the cell-
subjectsexposedtostudyvaccinewithsolicitedlocalandsystemic
derived A/H1N1 monovalent vaccine in healthy children and
reactionsandunsolicitedAEsreportedpergroup.Solicitedreac-
adolescents. Secondary objectives included evaluation of long-
tionsoccurringwithin7dposteachvaccinationwereconsidered
term persistence of antibodies andvaccine safety throughout the
indicators of reactogenicity that might possibly be related to
study.
study vaccine. These included local and systemic reactions col-
lectedfor7dfollowingeachvaccination.
Subjects All unsolicitedAEs were collectedfor 3weeks followingeach
Eligible subjects were healthy males and females aged 6 vaccination. All AEs resulting in study discontinuation, SAEs,
onset of chronic health conditions, and associated medications
months to 17 y on the day of enrollment without documented
werecollectedforthewholestudy(i.e.,days1–546).
influenza in the 3 months preceding enrollment. Influenza was
considereddocumentedbypositiveserologytest,viralculture,or
Statisticalanalysis
rapid antigen tests. Exclusion criteria are detailed in the supple-
Approximately720subjects(80peragegroupreceivingadju-
mentarysection.
Four cohorts were enrolled: children aged 9–17 y (cohort 1), vanted vaccines; 40 per age group in cohorts 2 and 3 receiving
3–8 y (cohort 2), 1–<3 years (cohort 3), and 6–11 months non-adjuvanted vaccines) were planned for study enrollment to
(cohort4). provide adequate power for evaluation of the primary endpoint.
Sample size was defined as sufficient to provide adequate esti-
matesfortheendpointsspecifiedintheCHMPcriteria,andwas
Vaccines calculated to demonstrate non-inferiority with a power of 90%,
Eachsubjectreceived2dosesofoneof3vaccineformulations if the real GMT ratio is 0.93.The full analysis set included all
(3.75_halfMF59, 7.5_fullMF59 and 15_noMF59 containing subjects who received a study vaccination and provided at least
3.75,7.5and15 mgA/H1N1and0.125,0.25and0 mLMF59 one evaluable serum sample before and after baseline. The per-
adjuvant, respectively), (Supplementary Table 1) administered protocolset(PPS)comprisedallsubjectswhoreceivedthecorrect
approximately3weeksapart.Oneyearafterthefirstvaccination, dosesofvaccine,providedevaluableserumsamplesattheappro-
subjectsreceivedaboosterwiththetrivalentseasonalMF59vac- priate time points, and had no major protocol violations. The
(cid:1)
cine (Fluad ) recommended for the 2010/11 influenza season PPS was the primary analysis set for the immunogenicity
(15 mg antigen from each influenza strain [including A/H1N1] analyses.
C 0.35 mL MF59). A second dose of trivalent seasonal vaccine Immunogenicity criteria comprised those of the CHMP for
was administered 3 weeks after the booster to na€ıve subjects adults,31including:1)thepercentageofsubjectswithseroconver-
<9 years of age, to complete the primary immunization against sion or significant increase in HI antibody is >40%; 2) the per-
influenza according to WHO recommendations. Vaccinations centageofsubjectsachievinganHItiter(cid:1)1:40is>70%;and3)
wereadministeredbyintramuscularinjectioninthedeltoidmus- GMR is (cid:1)2.5. All three criteria assessed at day 43 and at least
cleofthenon-dominantarmandtheanterolateralthighforchil- oneofthe3criteriaassessed3weekspost-boosterdosehadtobe
dren(cid:1)24monthsand<24months,respectively. met by each cohort to fulfill regulatory requirements. Results
374 HumanVaccines&Immunotherapeutics Volume11Issue2
from day 22 following the first vaccination were also evaluated UK) and funded by Novartis Vaccines. Editorial support was
against these criteria. Vaccine group differences were assessed providedbyDrsYvonnaFisher-JeffesandShanthiVoorn.
using 2-way analysis of variance with factors for vaccine group
andcenter.
Thesafetypopulationincludedallsubjectswhoreceivedstudy Funding
vaccination and provided post-baseline safety data. Descriptive This study was supported by funds provided by Novartis
statistics were calculated for all safety data and expressed as the Vaccines.
proportion and number of subjects with solicited local or sys-
temic reactions, unsolicited AEs, SAEs, and AEs resulting in
study discontinuation. All statistical analyses were performed by SupplementalMaterial
NovartisVaccinesusingSAS,version9.1orhigher. Supplementaldataforthisarticlecanbeaccessedonthepub-
lisher’swebsite.
DisclosureofPotentialConflictsofInterest
MK received honoraria and compensation of travel expenses
AuthorContributions
from Novartis, Astra Zeneca and GSK for presentations and
MK, GL-R, HR, LR and DK participated in the conduct of
advisory activities. GL-R received honoraria and compensation
thestudy,dataacquisitionandinterpretation,andcontributedto
of travel expenses from Novartis, GSK and Immune Targeting
the development of the initial draft of the manuscript, reviewed
Systems for presentations and advisory activities. H.R. and L.R,
andrevisedthemanuscript,andapprovedthefinalmanuscriptas
have no conflicts to report. PP, AKA, ML and GDC are full
submitted. PP participated in the conception, design, statistical
time employees of Novartis Vaccines companies. DK received
analyses,implementationofthestudy,interpretationofanalyzed
honoraria and compensation of travel expenses from Novartis,
data, contributed to the development of the initial draft of the
Wyeth/Pfizer andGSK forpresentations and advisoryactivities.
manuscript, reviewed and revised the manuscript, and approved
the final manuscript as submitted. AKA, ML and GDC partici-
Acknowledgments patedintheconception,designandimplementationofthestudy,
We would like to thank the study teams, the children and interpretation of analyzed data, and contributed to the develop-
their parents. Medical writing assistance for this manuscript was ment of the initial draftof themanuscript, reviewed and revised
providedbyDrHelenSwainstonofBioscriptMedical(London, themanuscript,andapprovedthefinalmanuscriptassubmitted.
References 8. YangY,SugimotoJD,HalloranME,BastaNE,Chao 14. Esposito S, Meregalli E, Daleno C, Peia F, Scala A,
1. HealthProtectionAgency.Pandemic(H1N1)2009in DL, Matrajt L, Potter G, Kenah E, Longini IM Jr.. SerraD,MirraN,GaleoneC,PrincipiN.Anopen-
England:anoverviewofinitialepidemiologicalfindings Thetransmissibilityandcontrolofpandemicinfluenza label,randomizedclinicaltrialassessingimmunogenic-
andimplicationsforthesecondwave(v42December A (H1N1) virus. Science 2009; 326:729-33; ity, safety and tolerability of pandemic influenza A/
2009).Availablefrom:http://webarchive.nationalarch- PMID:19745114; http://dx.doi.org/10.1126/science. H1N1MF59-adjuvantedvaccineadministeredsequen-
ives.gov.uk/20140714084352/http://www.hpa.org.uk/ 1177373 tiallyorsimultaneouslywithseasonalvirosomal-adju-
web/HPAwebFile/HPAweb_C/1258560552857 9. JordanR,ConnockM,AlbonE,Fry-SmithA,Olowo- vantedinfluenzavaccinetopaediatrickidneytransplant
2. MillerE,HoschlerK,HardelidP,StanfordE,Andrews kure B, Hawker J, Burls A. Universal vaccination of recipients.NephrolDialTransplant2011;26:2018-24;
N,ZambonM.Incidenceof2009pandemicinfluenza childrenagainstinfluenza:arethereindirectbenefitsto PMID:20974645; http://dx.doi.org/10.1093/ndt/
AH1N1infectioninEngland:across-sectionalsero- thecommunity?Asystematicreviewoftheevidence. gfq657
logical study. Lancet 2010; 375:1100-8; Vaccine2006; 24:1047-62;PMID:16298026;http:// 15. EspositoS,TagliaferriL,DalenoC,ValzanoA,Pic-
PMID:20096450; http://dx.doi.org/10.1016/S0140- dx.doi.org/10.1016/j.vaccine.2005.09.017 ciolliI,TelF,PrunottoG,SerraD,GaleoneC,Plebani
6736(09)62126-7 10. ClarkTW,PareekM,HoschlerK,DillonH,Nich- A,etal.PandemicinfluenzaA/H1N1vaccineadminis-
3. Sachedina N, Donaldson LJ. Paediatric mortality olson KG, Groth N, Stephenson I. Trial of 2009 teredsequentiallyorsimultaneouslywithseasonalinflu-
related to pandemic influenza A H1N1 infection in influenza A (H1N1) monovalent MF59-adjuvanted enzavaccinetoHIV-infectedchildrenandadolescents.
England: an observational population-based study. vaccine. N Engl J Med 2009; 361:2424-35; Vaccine 2011; 29:1677-82; PMID:21199699;http://
Lancet2010;376:1846-52; PMID:21030071;http:// PMID:19745215; http://dx.doi.org/10.1056/NEJMoa dx.doi.org/10.1016/j.vaccine.2010.12.047
dx.doi.org/10.1016/S0140-6736(10)61195-6 0907650 16. Kajaste-RudnitskiA,GalliL,NozzaS,TambussiG,Di
4. WorldHealthOrganization.NewinfluenzaA(H1N1) 11. AlghisiF,PalmaP,MontemitroE,BernardiS,Pon- PietroA,PellicciottaG,MontiA,MascagniP,Moro
virus: global epidemiological situation, June 2009. trelliG,RossiP,LucidiV.Immunogenicityandsafety M, Vicenzi E. Induction of protective antibody
Wkly Epidemiol Rec 2009; 84:249-60; profileofthemonovalentA/H1N1MF59-adjuvanted response by MF59-adjuvanted 2009 pandemic A/
PMID:19537358 vaccinein patientsaffected bycystic fibrosis. Thorax H1N1vinfluenzavaccineinHIV-1-infectedindividu-
5. GlezenWP,CouchRB.Interpandemicinfluenzainthe 2011;66:259-60;PMID:21228426;http://dx.doi.org/ als.AIDS2011;25:177-83;PMID:21150561;http://
Houstonarea,1974-76.NEnglJMed1978;298:587- 10.1136/thx.2010.156018 dx.doi.org/10.1097/QAD.0b013e328341afa8
92; PMID:628375; http://dx.doi.org/10.1056/ 12. BanzhoffA,HaertelS,PrausM.Passivesurveillanceof 17. PellegriniM,NicolayU,LindertK,GrothN,Della
NEJM197803162981103 adverseeventsofanMF59-adjuvantedH1N1vvaccine Cioppa G. MF59-adjuvanted versus non-adjuvanted
6. BastaNE,ChaoDL,HalloranME,MatrajtL,Longini duringthepandemicmassvaccinations.HumVaccin influenza vaccines: integrated analysis from a large
IM,Jr.Strategiesforpandemicandseasonalinfluenza 2011; 7:539-48; PMID:21422814; http://dx.doi.org/ safety database. Vaccine 2009; 27:6959-65;
vaccinationofschoolchildrenintheUnitedStates.Am 10.4161/hv.7.5.14821 PMID:19751689; http://dx.doi.org/10.1016/j.
J Epidemiol 2009; 170:679-86; PMID:19679750; 13. Esposito S,D’Angelo E,Daleno C,PeiaF,ScalaA, vaccine.2009.08.101
http://dx.doi.org/10.1093/aje/kwp237 SerraD,MirraN,GaleoneC,PrincipiN.Immunoge- 18. SchultzeV,D’AgostoV,WackA,NovickiD,ZornJ,
7. MedlockJ,GalvaniAP.Optimizinginfluenzavaccine nicity,safetyandtolerabilityofmonovalent2009pan- Hennig R. Safety of MF59 adjuvant. Vaccine 2008;
distribution. Science 2009; 325:1705-8; demicinfluenzaA/H1N1MF59-adjuvantedvaccinein 26:3209-22; PMID:18462843; http://dx.doi.org/
PMID:19696313; http://dx.doi.org/10.1126/ patients with beta-thalassemia major. Vaccine 2010; 10.1016/j.vaccine.2008.03.093
science.1175570 28:7825-8; PMID:20888873; http://dx.doi.org/ 19. TsaiTF,CrucittiA,NacciP,NicolayU,DellaCioppa
10.1016/j.vaccine.2010.09.058 G,FergusonJ,ClemensR.Explorationsofclinicaltri-
als and pharmacovigilance databases of MF59((R))-
www.tandfonline.com HumanVaccines&Immunotherapeutics 375
adjuvanted influenza vaccines for associated cases of 24. TsaiT,KyawMH,NovickiD,NacciP,RaiS,Clem- Hemagglutinationinhibitionantibodytitersasacorre-
narcolepsy. Scand J Infect Dis 2011; 43:702-6; ens R. Exposure to MF59-adjuvanted influenza vac- lateofprotectionforinactivatedinfluenzavaccinesin
PMID:21534891 cines during pregnancy–a retrospective analysis. children. Pediatr Infect Dis J 2011; 30:1081-5;
20. BanzhoffA,PellegriniM,DelGiudiceG,FragapaneE, Vaccine2010; 28:1877-80;PMID:19969117;http:// PMID:21983214; http://dx.doi.org/10.1097/INF.
GrothN,PoddaA.MF59-adjuvantedvaccinesforsea- dx.doi.org/10.1016/j.vaccine.2009.11.077 0b013e3182367662
sonal and pandemic influenza prophylaxis. Influenza 25. Globalalertandresponse:WHOrecommendationson 29. Beyer WE, Nauta JJ, Palache AM, Giezeman KM,
Other Respir Viruses 2008; 2:243-9; pandemic (H1N1) 2009 vaccines. Geneva. World Osterhaus AD.Immunogenicity and safety of inacti-
PMID:19453401; http://dx.doi.org/10.1111/j.1750- Health Organization, 2009. Available from: http:// vatedinfluenzavaccinesinprimedpopulations:asys-
2659.2008.00059.x www.who.int/csr/disease/swineflu/notes/h1n1_vac tematic literature review and meta-analysis. Vaccine
21. DurandoP,IcardiG,AnsaldiF.MF59-adjuvantedvac- cine_20090713/en/index.html 2011; 29:5785-92; PMID:21624411; http://dx.doi.
cine:asafeandusefultooltoenhanceandbroadenpro- 26. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche org/10.1016/j.vaccine.2011.05.040
tectionagainstseasonalinfluenzavirusesinsubjectsat MK,DenisM.Immuneresponseafterasinglevaccina- 30. VesikariT,PellegriniM,KarvonenA,GrothN,Bor-
risk. Expert Opin Biol Ther 2010; 10:639-51; tionagainst2009influenzaAH1N1inUSA:aprelimi- kowskiA,O’HaganDT,PoddaA.Enhancedimmuno-
PMID:20218923; http://dx.doi.org/10.1517/ naryreportoftworandomisedcontrolledphase2trials. genicity of seasonal influenza vaccines in young
14712591003724662 Lancet 2010; 375:41-8; PMID:20018365; http://dx. children using MF59 adjuvant. Pediatr Infect Dis J
22. ElSahlyH.MF59™asavaccineadjuvant:areviewof doi.org/10.1016/S0140-6736(09)62026-2 2009;28:563-71;PMID:19561422;http://dx.doi.org/
safetyandimmunogenicity.ExpertRevVaccines2010; 27. OhCE,LeeJ,KangJH,HongYJ,KimYK,Cheong 10.1097/INF.0b013e31819d6394
9:1135-41; PMID:20923265; http://dx.doi.org/ HJ,AhnYJ,KimSH,LeeHJ.Safetyandimmunoge- 31. European Medicines Agency. CPMP/BWP/214/96
10.1586/erv.10.111 nicityofaninactivatedsplit-virusinfluenzaA/H1N1 Noteforguidanceonharmonizationofrequirements
23. O’HaganDT.MF59isasafeandpotentvaccineadju- vaccineinhealthychildrenfrom6monthsto.Vaccine for influenza vaccines. Available from: http://www.
vant that enhances protection against influenza virus 2010; 28:5857-63; PMID:20600483; http://dx.doi. ema.europa.eu/ema/pages/includes/document/open_do
infection. Expert Rev Vaccines 2007; 6:699-710; org/10.1016/j.vaccine.2010.06.060 cument.jsp?webContentIdDWC500003945
PMID:17931151; http://dx.doi.org/10.1586/ 28. BlackS,NicolayU,VesikariT,KnufM,DelGiudice
14760584.6.5.699 G,DellaCioppaG,TsaiT,ClemensR,RappuoliR.
376 HumanVaccines&Immunotherapeutics Volume11Issue2
